Why this matters
Hypofractionation can substantially reduce the burden of postprostatectomy radiotherapy, but shortening treatment is only worthwhile if long-term urinary and bowel outcomes remain acceptable.
NRG-GU003 previously established noninferiority of hypofractionated postprostatectomy RT for patient-reported GU and GI toxicity at 2 years. The 5-year analysis addresses the more clinically relevant question of whether that advantage in convenience persists without a late toxicity penalty.
The answer is nuanced. Patient-reported outcomes remain similar, biochemical control remains comparable, but physician-reported grade 3 urinary toxicity is higher with hypofractionation.
Study design
NRG-GU003 randomized 296 men requiring postprostatectomy radiotherapy to:
- conventional postprostatectomy RT, 66.6 Gy in 37 fractions of 1.8 Gy
- hypofractionated postprostatectomy RT, 62.5 Gy in 25 fractions of 2.5 Gy
The hypofractionated schedule eliminates 12 treatment visits, reducing the number of fractions by approximately 32%.
Eligible patients had either detectable postoperative PSA with pT2-3 pNX/0 disease or undetectable PSA with pT3 disease or pT2 disease with a positive surgical margin.
Pelvic lymph node radiotherapy was not allowed. Patients were stratified by baseline EPIC score and use of ADT for up to 6 months.
The primary 5-year objective was to determine whether hypofractionated RT remained noninferior to conventional RT for patient-reported urinary and bowel symptoms. Additional outcomes included physician-reported toxicity, quality of life, biochemical failure, overall survival, and prostate cancer-specific survival.
Median follow-up was 7 years.
Key results
At 5 years, patient-reported urinary and bowel outcomes remained similar between the two treatment strategies.
For EPIC urinary change from baseline:
- conventional RT: -5.7
- hypofractionated RT: -8.0
- p=0.4
For EPIC bowel change:
- conventional RT: +0.6
- hypofractionated RT: -2.0
- p=0.1
Quality of life measured with EQ-5D was also similar at 5 years.
The physician-reported toxicity results, however, showed a clear difference.
Treatment-related grade 3 adverse events occurred in:
- 7% with conventional RT
- 16% with hypofractionated RT
- p=0.02
Grade 3 renal and urinary adverse events occurred in:
- 3% with conventional RT
- 13% with hypofractionated RT
- p=0.003
The difference was driven mainly by:
- noninfective cystitis: 0% vs 7%
- hematuria: 0.7% vs 5.6%
There were no treatment-related grade 4 or 5 adverse events.
Importantly, the higher physician-reported GU toxicity did not translate into a detectable long-term difference in patient-reported urinary outcomes.
Biochemical control was also similar. Five-year biochemical failure occurred in:
- 18% with conventional RT
- 21% with hypofractionated RT
- p=0.3
Interpretation
NRG-GU003 gives a more complicated answer than simply declaring hypofractionated postprostatectomy RT safe or unsafe.
From the patient's perspective, the long-term data remain reassuring. Urinary and bowel outcomes at 5 years were not meaningfully different, and the shorter schedule removes 12 treatment visits.
Disease control also appears similar, with no significant difference in biochemical failure.
But the physician-reported toxicity signal should not be ignored. Grade 3 urinary toxicity increased from 3% to 13%, driven predominantly by cystitis and hematuria.
This creates an important discrepancy between clinician-reported and patient-reported outcomes. Patients receiving hypofractionation did not report worse long-term urinary function despite more grade 3 urinary events being documented by physicians.
That distinction matters. A transient episode of hematuria or cystitis requiring medical intervention may qualify as grade 3 toxicity without necessarily producing a persistent decline in an EPIC urinary score years later.
The practical message is therefore not that hypofractionation comes without cost. It trades a substantially lower treatment burden for a modestly higher risk of clinically significant physician-reported urinary toxicity, without an apparent lasting penalty in patient-reported urinary or bowel function.
For many patients, that tradeoff may remain acceptable, but it should be part of treatment discussion rather than hidden behind the favorable patient-reported outcome data.
Limitations
Only 56% of patients completed EPIC questionnaires at 5 years, although the investigators evaluated missing data and reported that the discrepancy between physician-reported toxicity and patient-reported outcomes did not appear to be explained by missing questionnaires.
The trial evaluated prostate-bed radiotherapy without pelvic nodal irradiation, so the findings should not automatically be extrapolated to regimens that include pelvic lymph nodes.
The study was designed around patient-reported toxicity rather than oncologic noninferiority. Similar biochemical failure rates therefore support comparable disease control but do not formally establish oncologic equivalence.
Bottom line
The tradeoff is real: grade 3 urinary toxicity increased from 3% to 13%, primarily because of cystitis and hematuria.
The clinical decision is therefore not simply shorter versus longer treatment, but whether the reduction in treatment burden justifies a modest increase in physician-reported urinary toxicity for an individual patient.